The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC).
 
Holly Tovey
Research Funding - Merck Sharp & Dohme Ltd (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Employees of the ICR are subject to a "Rewards to Inventors Scheme" which may reward contributors to a programme that is subsequently licensed.
Other Relationship - Medivation (Inst)
 
Joel S. Parker
Stock and Other Ownership Interests - GeneCentric
Consulting or Advisory Role - Medivation
Patents, Royalties, Other Intellectual Property - Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.
 
Katherine A. Hoadley
No Relationships to Disclose
 
Richard D. Kennedy
Employment - Almac Diagnostics
Honoraria - AstraZeneca; Tesaro
 
Orsolya Sipos
No Relationships to Disclose
 
Lucy Kilburn
No Relationships to Disclose
 
Sarah Kernaghan
Other Relationship - Medivation (Inst)
 
Patrycja Gazinska
No Relationships to Disclose
 
Syed Haider
No Relationships to Disclose
 
Sarah E Pinder
Consulting or Advisory Role - Genomic Health; Roche
Speakers' Bureau - Genomic Health
 
Judith Bliss
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Charles M. Perou
Leadership - GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric
Consulting or Advisory Role - Bioclassifier; G1 Therapeutics; GeneCentric; Ions Pharmaceuticals
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
Travel, Accommodations, Expenses - Chugai Pharma; Takeda
 
Anita Grigoriadis
No Relationships to Disclose
 
Andrew Tutt
Stock and Other Ownership Interests - InBiomotion
Honoraria - Prime Oncology
Consulting or Advisory Role - Artios; AstraZeneca; InBiomotion; Medivation (Inst); Merck Serono (Inst); Myriad genetics; Pfizer; Prime Oncology; Vertex
Research Funding - AstraZeneca (Inst); Medivation (Inst); Myriad Genetics (Inst)
Patents, Royalties, Other Intellectual Property - I have i the past and may in the future be in Receipt of payments under my employer (ICR London) Rewards to inventors Scheme associated with patents held by ICR associated with the use of PARP inhibitors in BRCA 1/2 deficient cancers
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Maggie Chon U Cheang
Patents, Royalties, Other Intellectual Property - M.C.U.C. has a patent for Breast Cancer Classifier: US Patent No. 9,631,239 with royalties paid.
Other Relationship - Medivation